

# Caroline L Smith

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4893615/caroline-l-smith-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

9

papers

345

citations

6

h-index

9

g-index

9

ext. papers

384

ext. citations

4.7

avg, IF

3.03

L-index

| # | Paper  | IF   | Citations |
|---|--|------|-----------|
| 9 | Pregnancy influences the selection of appropriate reference genes in mouse tissue: Determination of appropriate reference genes for quantitative reverse transcription PCR studies in tissues from the female mouse reproductive axis. <i>Gene</i> , <b>2021</b> , 801, 145855 | 3.8  | 0         |
| 8 | Emerging roles of melanocortin receptor accessory proteins (MRAP and MRAP2) in physiology and pathophysiology. <i>Gene</i> , <b>2020</b> , 757, 144949   | 3.8  | 5         |
| 7 | Evaluating the benefits of virtual training for bioscience students. <i>Higher Education Pedagogies</i> , <b>2019</b> , 4, 287-299   | 1.2  | 13        |
| 6 | Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2008</b> , 294, H1530-40          | 5.2  | 159       |
| 5 | C-reactive protein and asymmetric dimethylarginine: markers or mediators in cardiovascular disorders?. <i>Current Pharmaceutical Design</i> , <b>2007</b> , 13, 1619-29  | 3.3  | 12        |
| 4 | Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase. <i>Journal of Medicinal Chemistry</i> , <b>2005</b> , 48, 4670-8  | 8.3  | 44        |
| 3 | Effects of ADMA upon gene expression: an insight into the pathophysiological significance of raised plasma ADMA. <i>PLoS Medicine</i> , <b>2005</b> , 2, e264  | 11.6 | 42        |
| 2 | Cardiovascular tests: use & limits of biochemical markers - therapeutic measurements of ADMA involved in cardiovascular disorders. <i>Current Pharmaceutical Design</i> , <b>2005</b> , 11, 2177-85  | 3.3  | 5         |
| 1 | Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. <i>Biochemical and Biophysical Research Communications</i> , <b>2003</b> , 308, 984-9   | 3.4  | 65        |